Key Points
- Raymond Woo sold 8,087 shares of CeriBell on March 2 at an average price of $18.25 for $147,587.75, reducing his holdings to 166,912 shares (a 4.62% cut) after additional sales in January and February.
- CeriBell beat the quarter's estimates, reporting a ($0.36) loss per share versus a ($0.43) consensus and $24.78 million in revenue, though the company still shows negative margins and return on equity.
- Analyst sentiment is mildly bullish—MarketBeat shows an average rating of "Moderate Buy" with an average price target of $24.67, while the stock trades near $17.96 within a 52-week range of $10.01–$24.33.
CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) CTO Raymond Woo sold 8,087 shares of CeriBell stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $18.25, for a total transaction of $147,587.75. Following the transaction, the chief technology officer owned 166,912 shares of the company's stock, valued at approximately $3,046,144. The trade was a 4.62% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Raymond Woo also recently made the following trade(s):
- On Monday, February 23rd, Raymond Woo sold 705 shares of CeriBell stock. The stock was sold at an average price of $19.79, for a total value of $13,951.95.
- On Friday, January 2nd, Raymond Woo sold 11,112 shares of CeriBell stock. The shares were sold at an average price of $21.18, for a total value of $235,352.16.
CeriBell Price Performance
Shares of NASDAQ:CBLL traded up $0.19 on Thursday, hitting $17.96. The company had a trading volume of 63,397 shares, compared to its average volume of 343,432. The company has a market cap of $676.03 million, a PE ratio of -12.22 and a beta of 1.12. The business has a 50 day moving average of $20.91 and a 200 day moving average of $16.41. CeriBell, Inc. has a 52-week low of $10.01 and a 52-week high of $24.33. The company has a current ratio of 9.73, a quick ratio of 9.35 and a debt-to-equity ratio of 0.13.
CeriBell (NASDAQ:CBLL - Get Free Report) last announced its earnings results on Tuesday, February 24th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.07. CeriBell had a negative net margin of 59.97% and a negative return on equity of 31.77%. The firm had revenue of $24.78 million during the quarter, compared to the consensus estimate of $23.95 million. As a group, equities analysts anticipate that CeriBell, Inc. will post -2.46 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several analysts have commented on CBLL shares. BTIG Research reaffirmed a "buy" rating and issued a $30.00 target price on shares of CeriBell in a research note on Wednesday, January 28th. JPMorgan Chase & Co. lowered their price objective on CeriBell from $21.00 to $17.00 and set an "overweight" rating for the company in a research report on Wednesday, November 5th. TD Cowen reiterated a "buy" rating on shares of CeriBell in a research note on Tuesday, December 9th. Finally, Canaccord Genuity Group raised their price target on CeriBell from $29.00 to $30.00 and gave the stock a "buy" rating in a research note on Wednesday, December 17th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, CeriBell currently has an average rating of "Moderate Buy" and an average price target of $24.67.
View Our Latest Report on CeriBell
Hedge Funds Weigh In On CeriBell
A number of large investors have recently modified their holdings of the company. Russell Investments Group Ltd. grew its holdings in shares of CeriBell by 41.4% during the 4th quarter. Russell Investments Group Ltd. now owns 2,918 shares of the company's stock worth $64,000 after purchasing an additional 854 shares during the period. Caitong International Asset Management Co. Ltd lifted its position in CeriBell by 3,971.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company's stock valued at $28,000 after buying an additional 1,231 shares in the last quarter. Ameritas Investment Partners Inc. grew its stake in CeriBell by 97.5% during the second quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company's stock worth $48,000 after buying an additional 1,256 shares during the period. Deutsche Bank AG increased its position in shares of CeriBell by 1.7% in the fourth quarter. Deutsche Bank AG now owns 85,182 shares of the company's stock worth $1,868,000 after acquiring an additional 1,393 shares in the last quarter. Finally, Royal Bank of Canada raised its stake in shares of CeriBell by 10.8% in the 4th quarter. Royal Bank of Canada now owns 15,588 shares of the company's stock valued at $342,000 after acquiring an additional 1,514 shares during the period.
CeriBell Company Profile
(
Get Free Report)
CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell's solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.
The company's product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
